A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group
The administration of chemoimmunotherapy in the postconsolidation setting after tandem ASCT is feasible and tolerable. Future studies will be needed to define the population most likely to benefit from this augmented postconsolidation therapy.
Authors
- Sean Green
- Wendy Fitzgerald (ORCID: https://orcid.org/0000-0001-5752-8250)
- Julie R. Park (ORCID: https://orcid.org/0000-0002-6777-9165)
- Araz Marachelian (ORCID: https://orcid.org/0000-0003-3857-4782)
- Ami Vijay Desai (ORCID: https://orcid.org/0000-0001-9658-3156)
- Rochelle Bagatell (ORCID: https://orcid.org/0000-0002-5729-8819)
- Meaghan Granger (ORCID: https://orcid.org/0000-0002-5500-0927)
- Brian LaBarre (ORCID: https://orcid.org/0009-0001-6566-6861)
- S. Dubois
- Mariel Trunzo
- Kelly C. Goldsmith (ORCID: https://orcid.org/0000-0001-8672-2298)
- Arlene Naranjo
- Lisa States
- Lulu Chen
Institutions
- Children's Oncology Group (CH)
- St. Jude Children's Research Hospital (US)
- Lucile Packard Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Children's Hospital of Los Angeles (US)
- University of Chicago (US)
- Children's Oncology Group (US)
- Children's Healthcare of Atlanta (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Pennsylvania (US)
- Philadelphia University (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1002/cncr.70165
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00